Gain Therapeutics, Inc. Common Stock (GANX) Stock
Key stats
- Market cap
- $49.42M
- Price / Earnings ratio
- -2.3x
- EPS (TTM)
- -$0.50
- Volume
- Loading
- 52-week high
- $4.34
- 52-week low
- $0.94
Source: third-party data provider, as of November 13, 2026
Compare with GANX
Technical indicators
- RSI 14
- 37.80
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.14
- MACD histogram
- 0.01
- SMA 50
- $1.50
- Price below SMA 50
- EMA 50
- $1.41
- Price below EMA 50
- SMA 200
- $1.82
- Price below SMA 200
- EMA 200
- $1.90
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About Gain Therapeutics, Inc. Common Stock
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Gene Mack M.B.A. | President, CEO & Director | 1974 |
| Dr. Khalid Islam Ph.D. | Chairman & Founder | 1955 |
| Dr. Terenzio Ignoni Pharm.D. | Chief Operating Officer | — |
| Mr. Gianluca Fuggetta | Senior VP of Finance & Principal Financial Officer | 1989 |
| Dr. Joanne Taylor Ph.D. | Chief Scientific Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 37.80
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.14
- MACD histogram
- 0.01
- SMA 50
- $1.50
- Price below SMA 50
- EMA 50
- $1.41
- Price below EMA 50
- SMA 200
- $1.82
- Price below SMA 200
- EMA 200
- $1.90
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $8.00
- Average
- $8.00
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.2 | -2.6 | +3.7 | +3.6 | -15.6 | +2.9 | -2.3 | -34.3 | -1.8 |
